Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Model scores of the 29,894 trials active now.

Model score 46% for any early termination, 24% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-01-12. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemialenalidomidetransplantcarcinomacell
  Phrases that lowered it: participantsdays beforevirus28trial
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 37.6% (raises risk) · Drug's FDA history
• Sponsor's past termination rate: 11.8% (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 36 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.5% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 65 (lowers risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Phase: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 102 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase I Study of Lenalidomide in Patients With Acute Leukemia NCT01615042 · started 2012 · scored riskier than 99% of active trials terminated
• Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML NCT02255162 · started 2015 · scored riskier than 95% of active trials terminated
• Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS NCT01133275 · started 2010 · scored riskier than 98% of active trials completed
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant NCT01419795 · started 2012 · scored riskier than 81% of active trials terminated
• Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) NCT00720850 · started 2008 · scored riskier than 89% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.